eDiagnosis(002932)2025-04-29 08:55Revenue and Profitability - The company's revenue for Q1 2025 was ¥69,960,271.60, representing a 14.76% increase compared to ¥60,963,422.30 in the same period last year[3] - The net profit attributable to shareholders was -¥3,662,988.06, a decline of 111.43% from ¥32,052,081.48 in the previous year[3] - Basic and diluted earnings per share were both -¥0.02, down 114.29% from ¥0.14 in the previous year[3] - Net profit for the current period was a loss of ¥3,405,173.99, compared to a profit of ¥28,108,162.20 in the previous period, indicating a significant decline[19] Cash Flow and Operating Activities - The net cash flow from operating activities was -¥30,524,488.33, a decrease of 166.81% compared to ¥45,688,082.68 in the same period last year[3] - Cash inflow from operating activities totaled ¥154,356,495.64, a decrease from ¥294,315,194.08 in the previous period[20] - Cash received from sales of goods and services was ¥146,015,819.62, down 36.40% from ¥229,599,558.61 in the previous year, indicating a slowdown in cash collection[8] - The total cash and cash equivalents at the end of the period decreased to 884.23 million, reflecting a substantial reduction[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,499,402,061.63, a decrease of 1.42% from ¥6,593,078,595.90 at the end of the previous year[3] - Current assets total 4,306,916,741.27 RMB, an increase from 2,397,670,406.85 RMB at the beginning of the period[14] - Total liabilities include short-term borrowings of 3,000,000.00 RMB and accounts payable of 248,241,215.03 RMB[14] - The total liabilities decreased from ¥574,401,155.88 to ¥499,733,047.11, reflecting a reduction in financial obligations[15] Operating Costs and Expenses - The company's operating costs increased by 60.69% to ¥58,506,453.08, primarily due to revenue growth and a decline in gross margin[8] - Total operating costs increased to ¥114,191,703.22, up 9.6% from ¥104,189,807.01 in the previous period, with operating costs specifically rising from ¥36,409,334.65 to ¥58,506,453.08[17][18] - Research and development expenses were reported at ¥24,550,271.02, down from ¥27,181,929.06 in the previous period, indicating a reduction in investment in innovation[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,981[10] - The top shareholder, Chen Lili, holds 27.06% of shares, totaling 62,918,895 shares[10] - The company has repurchased 13,034,741 shares, representing 5.61% of the total share capital[11] Credit and Impairment - The company reported a significant increase in credit impairment losses, amounting to ¥14,258,490.11, a rise of 307.19% compared to -¥6,881,817.36 in the previous year[8] - The company experienced a credit impairment loss of ¥14,258,490.11, compared to a gain of -¥6,881,817.36 in the previous period, highlighting increased credit risk[18] Government Subsidies - The company received government subsidies amounting to ¥23,500.00, which were significantly lower compared to previous periods[5] Audit Status - The first quarter report was not audited, which may affect the reliability of the financial data presented[23]